Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01619670
Other study ID # EKBB 235/11
Secondary ID
Status Terminated
Phase Phase 4
First received June 12, 2012
Last updated March 9, 2015
Start date June 2012
Est. completion date January 2015

Study information

Verified date March 2015
Source University Hospital, Basel, Switzerland
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Interventional

Clinical Trial Summary

Epidermolysis Bullosa (EB) is a very rare disease, with a severe impact on the life of the patient and the caregiver. Epidermolysis Bullosa (EB) comprises a group of genetically determined skin fragility disorders characterized by blistering of the skin and mucosae following mild mechanical trauma. There is no specific proven treatment for any form of EB, and the mainstay of clinical management is based on protection and avoidance of provoking factors. Chronic nonhealing erosions and ulcers have been treated with conventional split-thickness skin grafts. Alternatively some patients may benefit from the use of autologous or allogeneic cultured keratinocyte grafts.


Description:

Apligraf is a living bilayered cell therapy product. Apligraf is constructed of Type I bovine collagen. The mechanism of action of Apligraf is still unknown. No clinical evidence of rejection of Apligraf was observed when placed on acute or chronic wounds. Apligraf has been suggested to act as a "smart" material for wound healing by interacting with the surrounding environment to promote healing. It provides components with multiple actions, interacts with wounds in biological and physical ways, and appears to adapt to the wound environment and probably produces numerous pro-healing cytokines. The purpose of this study is to evaluate the use of Apligraf for the treatment of nonhealing wounds in subjects with epidermolysis bullosa. Apligraf will be evaluated for efficacy and safety compared to a conventional nonadherent dressing. The study is a pivotal, single center, within subject controlled observational trial in which the rate of wound healing, recurrence of EB lesions, subject report of pain will be compared to wounds treated with Control treatment. Subjects between 2 and 65 years of age, inclusive, with epidermolysis bullosa lesions will be screened for this study. For each subject at least two designated treatment sites will be selected. In case of two comparable treatment sites the most right side will receive Apligraf and the most left side will receive control. Efficacy will be assessed by clinical observations, wound tracings and photographs.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Both
Age group 2 Years to 65 Years
Eligibility Inclusion Criteria:

1. Subject is between 2 and 65 years of age.

2. Subject with clinical confirmed diagnosis of EB.

3. Subject has at least two lesions, if in a situation with two non-adjacent EB lesions, at least 4 cm apart.

4. Subject with EB lesions at least 2 cm2 present for at least 3weeks. For the purposes of this study, a lesion is defined as a wound resulting from a post blister erosion.

5. Subject who is a female of child-bearing potential (females >10 years of age) must have a documented negative urine or serum pregnancy test. Sexually active females must be practicing a medically proven form of contraception during the course of the study period.

6. Subject or legal guardian must have read, understood and signed an institutional review board (IRB) approved Informed Consent Form or Assent Form.

7. Subject and/or legal guardian must be able and willing to follow study procedures and instructions.

Exclusion Criteria:

- 1. Subject whose lesion has healed 20% or greater in area from post debridement (if applicable) Baseline Screen (Visit 1) to post debridement Day 0 (Visit 2) as determined by wound tracings.

2. Subject with uncontrolled diabetes mellitus (glycosylated HbA1C > 10%), cancer (biopsy confirmed active malignancy), or positive HIV test.

3. Subject is a child (<18 years of age) who is currently receiving or has received oral steroid therapy exceeding a total daily dose of 0.5mg/kg for more than two weeks, radiation or other immuno-suppressive therapy which would interfere with wound healing within the past four weeks.

4. Subject is an adult (>18 years of age) who is currently receiving or has received chronic high dose steroid therapy exceeding a total daily dose of 20mg for more than two weeks, radiation or other immuno-suppressive therapy which would interfere with wound healing within the past four weeks.

5. Subject who is currently on or has received topical steroidal therapy within 30 days before screening. Inhaled steroids are allowed.

6. Subject with the presence of acute infections in the areas intended for treatment.

7. Known hypersensitivity to bovine collagen or to the components of the Apligraf agarose shipping medium.

8. Subject who is lactating or pregnant (hCG positive as determined by lab testing).

9. Subject enrolled in any wound or investigational device study for any disease within the past four weeks.

10. Subject who has received an investigational drug or biological treatment within three months.

11. Subject with a history of alcohol or substance abuse within the previous year, which could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes.

12. Subject who, in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Apligraf
non adhesive layer

Locations

Country Name City State
Switzerland University Hospital Basel Basel

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Basel, Switzerland Organogenesis

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Other Pain Reduction of intensity of pain Study duration No
Primary Proportion of wounds Proportion of wounds first achieving 100 % epithelialization of tissue with the absence of drainage (i.e. complete wound closure) through study week 12. through study week 12 No
Secondary Time Time until 100 % epithelialization of wound tissue with the absence of drainage (i.e.complete wound closure). until 100% epithelialization No
See also
  Status Clinical Trial Phase
Completed NCT05045183 - A Study to Assess Wound Healing Efficacies of Different Clean, Treat, and Protect Wound Care Regimens Compared to Standard of Care and Untreated N/A
Enrolling by invitation NCT04613336 - Efficacy of Topical Heparin Spray on Donor Site Wound Healing Time Compared to Conventional Dressing Among Patients Undergoing Split Thickness Skin Grafting
Recruiting NCT02241811 - Wound Treatment With 3% Sodium Pentaborate Pentahydrate Phase 1
Completed NCT02797899 - Effect of PRF Palatal Bandage on Pain Scores and Wound Healing After Free Gingival Graft N/A
Completed NCT01227759 - Tyrosur® Gel-Investigation on Wound Healing Efficacy Phase 2
Completed NCT01061502 - Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds Phase 1/Phase 2
Completed NCT00736593 - A Study Evaluating Nexagon™ in the Treatment of Skin Wounds. Phase 1
Completed NCT00977951 - Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects Phase 1/Phase 2
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT05191082 - Manufacturing, Characterization and Evaluation of the Effect of Silk Fibroin Membranes, Loaded or Not With Neurotensins on Open Wounds in the Palate N/A
Enrolling by invitation NCT05942235 - The Use of Microlearning in Nursing Education
Completed NCT03433820 - Wound Healing in Healthy Volunteers N/A
Withdrawn NCT02383992 - Postoperative Care of Sutured Wounds N/A
Recruiting NCT02034539 - VADOplex Critical Limb Ischemia Study Phase 2/Phase 3
Recruiting NCT01680042 - Clinical Effect of Phenytoin Mucoadhesive Paste on Wound Healing After Oral Biopsy Phase 1
Completed NCT01734317 - An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver. N/A
Withdrawn NCT01008111 - Wound Healing of Incisional Wounds for Bilateral Hernia Repair Phase 1
Completed NCT01115218 - The Influence of Anterior Chamber Fluid Mediators on the Success Rate of Trabeculectomy
Terminated NCT00177060 - Topical Hydromorphone for Wound Healing Phase 1/Phase 2